About Our Expertise

Why B2S?

Development of contemporary biotherapeutics is complicated because of increased structural complexity and evolving treatment modalities.  B2S Life Sciences is uniquely qualified for achieving bioanalytical success as we are a Biotherapeutic Enablement Company. We leverage our combined expertise in custom critical reagents and regulated bioanalysis to deliver bioanalytical solutions for biotherapeutic drug candidates and diagnostics.

Our custom reagents are specifically designed, manufactured, and characterized to optimize their performance for the intended bioanalytical purpose. Moreover, we store all custom critical reagents in LCM+, our controlled proprietary life cycle inventory management system. This helps ensure long-term stability, consistency in performance and provides a well-documented chain-of-custody for regulatory compliance. When combined with our extensive range of complementary downstream services, we are uniquely qualified to deliver R&D services to pharma, biotech, CROs and diagnostic companies.

Our History and Evolution in Biotherapeutic R&D.

Today the B2S Life Sciences’ team has over 100 years of combined experience in biotherapeutic R&D. Our experience enables us to design and implement bioanalytical strategies that utilize high quality critical reagents and data analytics to deliver optimized solutions for clients.

2003

2014

2015

2016

2018

2019

2022

2023

In 2003 Ronald Bowsher, PhD, Wendell Smith, PhD and Rocco Brunelle, MS founded Bowsher, Brunelle and Smith, LLC (dba B2S Consulting) to provide clients with bioanalytical and statistical services to support R&D of biotherapeutics and conventional drugs.

By 2014 B2S Consulting has served hundreds of clients and made scientific contributions in manuscripts and presentations for bioanalysis of macromolecules, novel biomarkers and detection of antidrug antibodies.

Early in 2014 a new LLC was founded by Aleks Davis, MBA and Ronald Bowsher, PhD. and was rebranded as B2S Life Sciences, LLC

In 2015 B2S Life Sciences purchased a historic building in Franklin, Indiana and began building renovation.

In 2016 Began business focused on critical reagents and data analytics

In 2018 Initiated Assay Development Activities

Late in 2019 completed renovations and celebrated B2S facility open house

In 2019 B2S undertook creation of a laboratory to conduct GLP Bioanalysis

In Early 2022 B2S Life Sciences signed our 100th client!

In 2023 Initiated plans for expansion to a second facility

The Facility to Perform

B2S Facility

Renovated historic building

Take a tour
B2S Facility

Invested > $4 million in building & infrastructure

Looking for the facts?

Download our fact sheet

Our Core Mission

At B2S Life Sciences, our mission is to leverage our extensive expertise in bioanalytical science and biotherapeutic drug development to ensure the technical success for our clients’ therapeutic products and devices. We strive to create value and drive positive impact in discovery, development projects, and regulatory submissions. By combining cutting-edge laboratory analysis with comprehensive lifecycle management of custom reagents, we support our clients in achieving their goals and advancing the field of biotherapeutics.

Vision for the Future

Since our inception in 2002 as Bowsher Brunelle Smith LLC, we have continually evolved to meet the changing needs of the pharmaceutical and biotherapeutic industries. Today, as B2S Life Sciences, we are poised to lead the way in biotherapeutic enablement, offering premier laboratory services and innovative solutions.

How we support the industry

  • Regulated Bioanalysis and Ligand Binding Assays: Providing accurate and reliable data to support drug development.
  • Support for Proteins, Peptides, and Biosimilars: Delivering specialized expertise in biotherapeutic product development.
  • Immunogenicity and Immune Safety Testing: Ensuring the safety and efficacy of therapeutic products through rigorous testing and cut-point data analytics
  • Chemistry, Manufacturing, and Controls (CMC): Providing comprehensive support for protein formulation and regulatory compliance.
  • Regulatory Sciences and Quality Compliance: Guiding clients through the regulatory landscape with expert advice and support.

Our Values

Innovation and Growth

Innovation and Growth

We are committed to staying at the forefront of biotherapeutic innovation, continually expanding our services and capabilities.

Client-Centric Approach

Client-Centric Approach

Our focus remains on building strong, collaborative relationships with our clients, understanding their unique needs, and providing tailored solutions.

Sustainable Impact

Sustainable Impact

We aim to make a lasting positive impact on the industry by promoting sustainability, ethical practices, and scientific excellence.

Expanding Capabilities

Expanding Capabilities

As we look to the future, we are dedicated to broadening our service offerings, embracing new technologies, and fostering a culture of continuous improvement.

Meet Our Executive Team

Ronald R. Bowsher PH.D.

Partner & Chief Scientific Officer

Dr. Bowsher’s career in the pharmaceutical/biotechnology and CRO industries has spanned 41⁄2 decade, including 3 decades at the Lilly Research Labs and nearly 2 decades as a consultant and an advisor in the CRO industry. He is a recognized thought-leader in the areas of bioanalytical methods development for regulatory-compliant bioanalysis, ADME and immunogenicity assessments of biotherapeutics. He received his M.S. and Ph.D. degrees in Biochemistry & Molecular Biology at the Indiana University School of Medicine (Indianapolis, IN). Currently, he is Partner and CSO at B2S Life SciencesTM (www.B2SLifeSciences.com), a biotechnology drug development support laboratory in Franklin, IN specializing in the generation and life-cycle management of custom biological reagents, ligand binding assay development and ADME, and data analytics to support biotherapeutic drug development.

Aleks Davis BS, MBA

Partner & Chief Executive Officer

Aleks Davis has over twenty years of experience in biotechnology industry with a proven track record in multiple facets of drug development. As a project director in Tailored Therapeutics at Eli Lilly and Company, Aleks was responsible for the planning, implementation and financial tracking of projects supporting early stage biomarker hypothesis. Several of these projects were in the neuroscience field. As the global director at ICON PLC, Aleks developed policies and procedures, business development strategies, marketing and profit and loss accountability. There he directed operations spanning four continents. Now at B2S Life Sciences, Aleks is the CEO and works with over one hundred different clients by helping them navigate the important, yet, challenging aspects of bioanalysis in biotherapeutic development. His Chemistry degree is from Georgia Southern University and Executive MBA is from Kelley School of Business, Indiana University. In 2019, he was a member of the B2S Life Sciences team that was honored by the Small Business Administration as Indiana’s Exporter of the Year.

Technical Operations & Logistics Team

By integrating our rich history with a forward-looking perspective, B2S Life Sciences is dedicated to empowering our clients and driving advancements in the biotherapeutic industry. Join us on this journey as we continue to innovate, grow, and make a meaningful difference in the world of healthcare.

©2025 B2S Life Science. All Rights Reserved.

Website design by Mentus

©2025 B2S Life Science. All Rights Reserved.

Website design by Mentus